Last reviewed · How we verify
Motazomin (MOLSIDOMINE)
Motazomin (generic name: MOLSIDOMINE) is a molsidomine drug. It is currently in Phase 2 development for Angina pectoris.
Molsidomine works by releasing nitric oxide, which relaxes blood vessels and improves blood flow to the heart.
Motazomin is a small molecule with the CAS number 276. It is also known by the synonyms CAS 276, CAS-276, CAS276, CORVASAL, CORVATON MITE, and CORVATON RET.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MOLSIDOMINE |
|---|---|
| Drug class | molsidomine |
| Target | Estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Think of it like a traffic jam: when blood vessels are constricted, it's like a traffic jam in your body. Molsidomine helps to 'open up' these blood vessels, allowing blood to flow more easily and reducing the strain on your heart.
Approved indications
- Angina pectoris
Common side effects
- Toxic epidermal necrolysis
- Antinuclear antibody negative
- Product prescribing error
- Electrolyte imbalance
- General physical health deterioration
- Antiphospholipid syndrome
- Herpes simplex reactivation
- Dermatitis exfoliative
- Fall
- Hyperthyroidism
- Coombs positive haemolytic anaemia
- Cholecystitis
Key clinical trials
- Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris (PHASE4)
- Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Motazomin CI brief — competitive landscape report
- Motazomin updates RSS · CI watch RSS
Frequently asked questions about Motazomin
What is Motazomin?
How does Motazomin work?
What is Motazomin used for?
What is the generic name of Motazomin?
What drug class is Motazomin in?
What development phase is Motazomin in?
What are the side effects of Motazomin?
What does Motazomin target?
Related
- Drug class: All molsidomine drugs
- Target: All drugs targeting Estrogen receptor
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Angina pectoris
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing